4

OBJECTIVES:We adopted perimembranous (PM) ventricular septal defect (VSD) closure by using only femoral arterial access and choosing device size based on transthoracic echocardiography (TTE) without injection of contrast. Here, we have evaluated mid term results.METHODS: From December 2022 to December 2023, patients with PM VSD, who treated percutaneously were retrospectively analized. Patients age, body weight, procedure time, VSD size, used occluder size, complications were analized. The day after the procedure and one month later, routine electrocardiography (ECG) and TTE were performed to find or exclude any type of device-related arrhythmias, residual shunt, new onset AR, or TR.RESULTS:Among 56 patients, 28 were female, and the age median and range were 64 (14-180) months, Body weight 17,35 (8-70)kg. VSD sizewere 4,8 (3,2-7,8) mm. Procedure time were 40 (20-135) minutes. 13 patients had residual shunts less than 3mm, mainly due to the absence of fabric inside small devices, but one month later, it decreased to 8 patients. Nor new onset aortic regurgitation (AR) nither atrio-ventricular (AV) block observed. New mild TR occurred in 3 cases, likely due to tricuspid valve chordae entrapment and 1 patient had moderate TR. Device embolization occured in one case. The device was successfully retrieved by snare, and a 2mm larger device was implanted

  • Количество прочтений 4
  • Дата публикации 01-06-2024
  • Язык статьиIngliz
  • Страницы135-141
Ключевые слова
English

OBJECTIVES:We adopted perimembranous (PM) ventricular septal defect (VSD) closure by using only femoral arterial access and choosing device size based on transthoracic echocardiography (TTE) without injection of contrast. Here, we have evaluated mid term results.METHODS: From December 2022 to December 2023, patients with PM VSD, who treated percutaneously were retrospectively analized. Patients age, body weight, procedure time, VSD size, used occluder size, complications were analized. The day after the procedure and one month later, routine electrocardiography (ECG) and TTE were performed to find or exclude any type of device-related arrhythmias, residual shunt, new onset AR, or TR.RESULTS:Among 56 patients, 28 were female, and the age median and range were 64 (14-180) months, Body weight 17,35 (8-70)kg. VSD sizewere 4,8 (3,2-7,8) mm. Procedure time were 40 (20-135) minutes. 13 patients had residual shunts less than 3mm, mainly due to the absence of fabric inside small devices, but one month later, it decreased to 8 patients. Nor new onset aortic regurgitation (AR) nither atrio-ventricular (AV) block observed. New mild TR occurred in 3 cases, likely due to tricuspid valve chordae entrapment and 1 patient had moderate TR. Device embolization occured in one case. The device was successfully retrieved by snare, and a 2mm larger device was implanted

Ключевые слова
№ Название ссылки
1 1.Lock JE, Block PC, McKay RG, Baim DS, Keane JF. Transcatheter closure of ventricular septal defects. Circulation. 1988 Aug;78(2):361-8. doi: 10.1161/01.cir.78.2.361. PMID: 3396173.2.Rigby ML, Redington AN. Primary transcatheter umbrella closure of perimembranous ventricular septal defect. Br Heart J. 1994 Oct;72(4):368-71. doi: 10.1136/hrt.72.4.368. PMID: 7833197; PMCID: PMC1025549.3.Sideris EB, Walsh KP, Haddad JL, Chen CR, Ren SG, Kulkarni H. Occlusion of congenital ventricular septal defects by the buttoned device. "Buttoneddevice" Clinical Trials International Register. Heart. 1997 Mar;77(3):276-9. doi: 10.1136/hrt.77.3.276. PMID: 9093050; PMCID: PMC484698.4.Kalra GS, Verma PK, Singh S, Arora R. Transcatheter closure of ventricular septal defect using detachable steel coil. Heart. 1999 Sep;82(3):395-6. doi: 10.1136/hrt.82.3.395. PMID: 10455098; PMCID: PMC1729174.5.Hijazi ZM, Hakim F, Haweleh AA, Madani A, Tarawna W, Hiari A, Cao QL. Catheter closure of perimembranous ventricular septal defects using the new Amplatzer membranous VSD occluder: initial clinical experience. Catheter Cardiovasc Interv. 2002 Aug;56(4):508-15. doi: 10.1002/ccd.10292. PMID: 12124963.6.Kozlik-Feldmann R, Lorber A, Sievert H, Ewert P, Jux C, Müller GC, Dalla Pozza R, Yigitbasi M, Schranz D, Lindinger A, Galal O, Meinertz T. Long-term outcome of perimembranous VSD closure using the Nit-Occlud® Lê VSD coil system. Clin Res Cardiol. 2021 Mar;110(3):382-390. doi: 10.1007/s00392-020-01750-6. Epub 2020 Oct 31. PMID: 33128576; PMCID: PMC7906931.7.Suligoj B, CernicN, Zorc M, Noc M, Kar S. Retrograde transcatheter closure of ventricular septal defect with Amplatzer Duct Occluder II. Postepy Kardiol Interwencyjnej. 2016;12(2):177-8. doi: 10.5114/aic.2016.59371. Epub 2016 May 11. PMID: 27279880; PMCID: PMC4882393.8.Haddad RN, Daou LS, Saliba ZS. Percutaneous closure of restrictive-type perimembranous ventricular septal defect using the new KONAR multifunctional occluder: Midterm outcomes of the first Middle Eastern experience. Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E295-E302. doi: 10.1002/ccd.28678. Epub 2019 Dec 30. PMID: 31886940.9.Ece İ, Bağrul D, Kavurt AV, Terin H, Torun G, Koca S, Gül AEK. Transcatheter Ventricular Septal Defect Closure with Lifetech™ Konar-MF Occluder in Infants Under 10 kg with Only Using Venous Access. Pediatr Cardiol. 2024 Jan;45(1):175-183. Doi: 10.1007/s00246-023-03350-3. Epub 2023 Dec 11. PMID: 38081968.10.Kamalı H, Sivaslı Gül Ö, Çoban Ş, Sarı G, Sarıtaş T, Erdem A, Aldudak B. Experiences of Two Centers in Percutaneous Ventricular Septal Defect Closure Using Konar Multifunctional Occluder. Anatol J Cardiol. 2022 Apr;26(4):276-285. doi: 10.5152/AnatolJCardiol.2021.464. PMID: 35435839; PMCID: PMC9366381.11.Yildiz K, Narin N, Oksuz S, Ozdemir R, Pamukcu O, Baykan A, Ozyurt A, Bagli S, Aktas R, Safak IN, Atlan MA, Bayam YS, Karadeniz C. Safety and efficacy of Amplatzer duct occluder II and Konar-MF™ VSD.12.Kuswiyanto RB, Gunawijaya E, Djer MM, Noormanto, Rahman MA, Murni IK, Sukardi R, Utamayasa A, Ardiansyah R, Nova R, Liliyanti S, Rahayuningsih SE, Anggriawan SL, Rahayuningsih TY, Koentartiwi D, Soewarniaty R, Yantie VK, Nugroho S, Hidayat T, Ontoseno T, Tobing TC, Ali M, Bashari MH, Yosy DS, Arafuri N, Hilmanto D, Yanuarso PB, Advani N, Sastroasmoro S, Putra ST. Transcatheter Closure of Perimembranous Ventricular Septal Defect Using the Lifetech Konar-Multi Functional Occluder: Early to Midterm Results of the Indonesian Multicenter Study. Glob Heart. 2022 Feb 24;17(1):15. doi: 10.5334/gh.1106. PMID: 35342698; PMCID: PMC8877696.13.Weryński P, Skorek P, Wójcik A, Rudek-Budzyńska A, Dziewulska A, Rudziński A. Recent achievements in transcatheter closure of ventricular septal defects: a systematic review of the literature and a meta-analysis. Kardiol Pol. 2021 Feb 25;79(2):161-169. Doi: 10.33963/KP.15708. Epub 2020 Dec 11. PMID: 33331744.14.Tanidir IC, Baspinar O, Saygi M, Kervancioglu M, Guzeltas A, Odemis E. Use of Lifetech™ Konar-MF, a device for both perimembranous and muscular ventricular septal defects: A multicentre study. Int J Cardiol. 2020 Jul 1;310:43-50. doi: 10.1016/j.ijcard.2020.02.056. Epub 2020 Feb 22. PMID: 32122701.15.Vogel M, Rigby ML, Shore D. Perforation of the right aortic valve cusp: complication of ventricular septal defect closure with a modified Rashkind umbrella. Pediatr Cardiol. 1996 Nov-Dec;17(6):416-8. Doi: 10.1007/s002469900093. PMID: 8781098.16.Martinez MW, Mookadam M, Mookadam F. A case of hemolysis after percutaneous ventricular septal defect closure with a device. J Invasive Cardiol. 2007 Jul;19(7):E192-4. PMID: 17620685.17.Sadiq M, Qureshi AU, Younas M, Arshad S, Hyder SN. Percutaneous closure of ventricular septal defect using LifeTechTMKonar-MF VSD Occluder: initial and short-term multi-institutional results. Cardiol Young. 2022 May;32(5):755-761. doi: 10.1017/S1047951121002985. Epub 2021 Jul 28. PMID: 34318740.18.Han Y, Li H, Zhu H, Sun G, Yin Q, Gu C. Aortic regurgitation after closure of ventricular septal defect by transcatheter device: the long-term complication. Cardiol Young. 2020 Apr;30(4):577-579. doi: 10.1017/S1047951120000414. Epub 2020 Feb 27. PMID: 32102719.q19.Jiang D, Zhang J, Fan Y, Han B, Zhao L, Yi Y, Lv J, Wang J. The Efficacy and Medium to Long-Term Follow-Up of Transcatheter Retrograde Closure of Perimembranous Ventricular Septal Defects via the Femoral Artery With Amplatzer Duct Occluder II in Children. Front Pediatr. 2021 May 25;9:571407. doi: 10.3389/fped.2021.571407. PMID: 34113582; PMCID: PMC8185017.20.Koneti NR, Sreeram N, Penumatsa RR, Arramraj SK, Karunakar V, Trieschmann U. Transcatheter retrograde closure of perimembranous ventricular septal defects in children with the Amplatzer duct occluder II device. J Am Coll Cardiol. 2012 Dec 11;60(23):2421-2. doi: 10.1016/j.jacc.2012.08.1004. Epub 2012 Nov 7. PMID: 23141497.
В ожидании